QxMD Adapts Scientific Papers into Interactive Clinical Decision Support Tools

Authors, publishers and medical affairs teams continue turning to
QxMD to convert decision support tools into interactive online and
app-based tools with built-in audience reach.

VANCOUVER, British Columbia–(BUSINESS WIRE)–lt;a href="https://twitter.com/hashtag/medicalapps?src=hash" target="_blank"gt;#medicalappslt;/agt;–QxMD
Software Inc., a digital learning technology company that makes it
easier for healthcare professionals (HCPs) to discover and apply the
latest evidence for use in clinical practice, today announced the
availability of its newest point-of-care clinical tool ‘International
IgA Nephropathy Prediction Tool’ for Calculate
by QxMD mobile and web app users. Coinciding with the JAMA
Internal Medicine e-publication of the paper ‘Evaluating
a New International Risk-Prediction Tool in IgA Nephropathy’ by Sean
J. Barbour, MD, MSc, Rosanna Coppo, MD, FERA, Hong Zhang, MD, PhD, and
others, the Internal IgAN Prediction Tool becomes the fourth Calculate
by QxMD tool to simultaneously publish with a peer-reviewed paper or
presentation since October 2018. The tool was also timed to go live at
the moment Dr Barbour presented at the 2019 ISN World Congress of
Nephrology in Melbourne.

“The QxMD publication tactic to include interactive calculators and
tools at the time of publication is a winning proposition for all
stakeholders, and an important strategy to achieve rapid knowledge
translation,” said QxMD CEO and Medical Director Daniel Schwartz, MD,
FRCPC. “Authors and affiliated organizations benefit from augmented
reach and impact for their research results. Publishers benefit from
additional publication brand visibility. Most importantly, patient
populations benefit from healthcare providers’ ability to access
resources that enhance early disease detection and diagnosis, medical
intervention, and therapeutic treatment optimization.”

The IgA Nephropathy Prediction Tool accurately predicts the long-term
risk of worsening kidney function at the time of kidney biopsy diagnosis
of IgA nephropathy – measured as a 50% reduction in kidney function
(eGFR) or the development of end-stage kidney disease. Developed by
members of the International IgAN Network who analyzed data from a large
number of adults with IgA nephropathy from around the world, the IgAN
Prediction Tool is most reliable in predicting the risk of kidney
function decline up to 5 years after kidney biopsy.

“IgA nephropathy is a highly variable condition, and patients who have
IgA nephropathy and the health professionals who support them have
always wanted a more accurate way of predicting future renal function
decline,” added Sean Barbour, MD, M.Sc., FRCPC, the study’s lead author
and assistant Professor, Division of Nephrology, Department of Medicine,
Faculty of Medicine, UBC. “With our International IgAN Prediction Tool
freely available on QxMD, it can be incorporated into regular care
planning and point-of-care engagement for patients with IgA nephropathy.
This is a major breakthrough and delivers on a key part of our knowledge
translation strategy since the beginning of this project.”

Calculate by QxMD is one of many free medical apps (Read
by QxMD, Learn
by QxMD) that comprise the QxMD Pathways platform. Together, these
apps provide millions of users with fast access to full-text research,
continuing medical education (CME), and up-to-date tools that drive
disease recognition and therapy optimization. Powered by a sophisticated
personalization engine, the platform aggregates PubMed feeds, journal
table of contents (TOCs), 450+ diagnostic tools, micro-learning CME
courses and more.

QxMD has a consistent history of publishing tools on Calculate by QxMD
simultaneously at the time of publication in a peer-reviewed paper or at
a conference presentation. The three most recent tools, VQI Same-Day
Discharge (October 2018), CLL Ball Score (November 2018) and ROKS 2018
(December 2018), were quickly used by thousands of global clinicians
shortly after publication. In addition to the Calculate by QxMD
publication tactic, QxMD also offers authors, publishers, and
professionals in publications and medical communications the ability to
transparently sponsor and disseminate research on the QxMD platform for
greater publication reach and share-of-voice.

To learn more about QxMD, please visit www.qxmd.com.

About QxMD
QxMD™ is a digital learning technology company
that makes it easier for healthcare professionals (HCPs) to discover the
latest evidence and decision support tools for use in clinical practice.
The company’s HCP engagement platform comprises a library of trusted
apps that provide millions of members with fast access to full-text
research, continuing medical education (CME), and up-to-date tools that
drive disease recognition and therapy optimization. Powered by a
sophisticated personalization engine, the platform aggregates PubMed
feeds, journal table of contents (TOCs), 450+ diagnostic tools,
micro-CME courses & more. QxMD also serves other healthcare constituents
such as hospitals, libraries, scholarly publishers, and nearly 50% of
the world’s top-25 pharmaceutical companies.

Contacts

Ian Palmer
QxMD Software Inc.
E: [email protected]
P:
+1 (415) 533-8308